tiprankstipranks
Advertisement
Advertisement

GLSI Stock Latest News

Greenwich LifeSciences reports cash balance of $10.5M as of March 31
The FlyGreenwich LifeSciences reports cash balance of $10.5M as of March 31
4d ago
GLSI
Greenwich LifeSciences updates on new patent claims based on FLAMINGO-01
PremiumThe Fly
Greenwich LifeSciences updates on new patent claims based on FLAMINGO-01
11d ago
GLSI
Greenwich LifeSciences Delays Annual SEC Filing
PremiumCompany Announcements
Greenwich LifeSciences Delays Annual SEC Filing
17d ago
GLSI
Greenwich LifeSciences adds City of Hope to FLAMINGO-01 trial
PremiumThe Fly
Greenwich LifeSciences adds City of Hope to FLAMINGO-01 trial
30d ago
GLSI
Greenwich LifeSciences provides update on presentations at AACR Meeting 2026
PremiumThe Fly
Greenwich LifeSciences provides update on presentations at AACR Meeting 2026
1M ago
GLSI
Greenwich LifeSciences’ GLSI-100 reduces recurrence rate in Phase 3 trial
PremiumThe FlyGreenwich LifeSciences’ GLSI-100 reduces recurrence rate in Phase 3 trial
1M ago
GLSI
Greenwich announces use of commercially manufactured GP2 in FLAMINGO-01
Premium
The Fly
Greenwich announces use of commercially manufactured GP2 in FLAMINGO-01
1M ago
GLSI
Greenwich LifeSciences provides update on screen rate in FLAMINGO-01 trial
Premium
The Fly
Greenwich LifeSciences provides update on screen rate in FLAMINGO-01 trial
2M ago
GLSI
Greenwich LifeSciences: Strengthened Liquidity and Robust GP2 Data Support Reiterated Buy and $50 Target
PremiumRatings
Greenwich LifeSciences: Strengthened Liquidity and Robust GP2 Data Support Reiterated Buy and $50 Target
2M ago
GLSI
Greenwich LifeSciences provides financial update on FLAMINGO-01 Phase 3 trial
PremiumThe Fly
Greenwich LifeSciences provides financial update on FLAMINGO-01 Phase 3 trial
3M ago
GLSI
Greenwich LifeSciences’ GP2 breast cancer therapy approved by FDA
PremiumThe Fly
Greenwich LifeSciences’ GP2 breast cancer therapy approved by FDA
3M ago
GLSI
GLSI-100’s Expanded Efficacy and Market Potential Drive Higher Valuation and Reiterated Buy Rating
PremiumRatings
GLSI-100’s Expanded Efficacy and Market Potential Drive Higher Valuation and Reiterated Buy Rating
4M ago
GLSI
Greenwich LifeSciences price target raised to $50 from $39 at H.C. Wainwright
PremiumThe FlyGreenwich LifeSciences price target raised to $50 from $39 at H.C. Wainwright
4M ago
GLSI
Greenwich LifeSciences extends lock-up of directors, officers to September 30
Premium
The Fly
Greenwich LifeSciences extends lock-up of directors, officers to September 30
4M ago
GLSI
Greenwich LifeSciences says burn rate for 2025 $7M through first three quarters
Premium
The Fly
Greenwich LifeSciences says burn rate for 2025 $7M through first three quarters
4M ago
GLSI
Greenwich LifeSciences provides update on FLAMINGO-01 trial
PremiumThe Fly
Greenwich LifeSciences provides update on FLAMINGO-01 trial
4M ago
GLSI
Greenwich LifeSciences Stockholders Reelect Board and Auditor
PremiumCompany Announcements
Greenwich LifeSciences Stockholders Reelect Board and Auditor
4M ago
8K
GLSI
Greenwich announces 80% recurrence rate reduction in FLAMINGO-01 arm
PremiumThe Fly
Greenwich announces 80% recurrence rate reduction in FLAMINGO-01 arm
4M ago
GLSI
Greenwich LifeSciences: Enrollment complete in open label arm oFLAMINGO-01 trial
PremiumThe Fly
Greenwich LifeSciences: Enrollment complete in open label arm oFLAMINGO-01 trial
4M ago
GLSI
Greenwich LifeSciences screens over 1,000 patients in Flamingo-01 cancer trial
PremiumThe FlyGreenwich LifeSciences screens over 1,000 patients in Flamingo-01 cancer trial
5M ago
GLSI
Greenwich Lifesciences Advances Phase 3 Breast Cancer Study with GLSI-100
Premium
Company Announcements
Greenwich Lifesciences Advances Phase 3 Breast Cancer Study with GLSI-100
6M ago
GLSI
Greenwich LifeSciences adds Austria to Flamingo-01 clinical trial
Premium
The Fly
Greenwich LifeSciences adds Austria to Flamingo-01 clinical trial
6M ago
GLSI

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >